MNPR Monopar Therapeutics
Pharmaceutical Preparations · Nasdaq · SEC CIK 1645469 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-15.3%
ROA-15.0%
ROIC (approx.)-45.6%
Asset turnover—
Leverage & solvency
Liabilities / assets2.4%
Debt / equity0.00x
Current ratio43.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | — | — | — |
| R&D expense | $9.90M | $13.01M | $5.60M | $7.59M | $6.49M |
| SG&A expense | $6.80M | $3.16M | $3.23M | $2.95M | $2.63M |
| Operating income | -$16.70M | -$16.16M | -$8.83M | -$10.54M | -$9.13M |
| Pretax income | -$13.72M | -$15.59M | -$8.40M | — | — |
| Income tax | $800 | $800 | $800 | $800 | $0 |
| Net income | -$13.72M | -$15.59M | -$8.40M | -$10.52M | -$9.10M |
| EPS (basic) | -1.85 | -4.11 | -3.04 | -0.83 | -0.73 |
| EPS (diluted) | — | — | — | — | -0.73 |
| Weighted avg. shares (diluted) | — | — | — | — | 12.47M |
| Banking | |||||
| Net interest income | — | — | $429,039 | $21,239 | $24,024 |
| Balance sheet | |||||
| Cash & equivalents | $61.83M | $45.82M | $7.27M | $8.19M | $20.30M |
| Short-term investments | $60.88M | $45.53M | $6.54M | $12.18M | — |
| Current assets | $140.46M | $60.29M | $7.33M | $13.17M | $20.52M |
| Total assets | $140.72M | $60.29M | $7.35M | $13.23M | $20.52M |
| Current liabilities | $2.74M | $5.25M | $1.76M | $3.13M | $1.58M |
| Total liabilities | $2.89M | $5.25M | $1.76M | $3.14M | $1.58M |
| Shareholders' equity | $137.83M | $55.04M | $5.59M | $10.09M | $18.94M |
| Shares outstanding | 6.69M | 6.10M | 2.98M | 12.95M | 12.60M |
| Cash flow statement | |||||
| Operating cash flow | -$12.20M | -$6.40M | -$7.86M | -$7.23M | -$7.32M |
| Investing cash flow | -$63.45M | -$14.34M | $4.93M | -$4.92M | $0 |
| Financing cash flow | $91.57M | $59.29M | $2.03M | $32,873 | $10.88M |
| Stock-based compensation | $4.84M | $1.14M | $1.90M | $1.64M | $1.47M |
| Share buybacks | $35.00M | $0 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.